Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) has scheduled its third quarter 2024 earnings conference call for November 7, 2024, at 4:30 pm ET, with results to be released after market close. Management will provide financial overview and business updates during the call. Additionally, the company announced participation in two upcoming investor healthcare conferences: The Guggenheim Inaugural Global Healthcare Conference on November 13, featuring CEO Paul J. Diaz, and The 6th Annual Wolfe Research Healthcare Conference on November 20, featuring CFO Scott Leffler and COO Sam Raha.

Management will also participate in two upcoming investor healthcare conferences

SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2024.

A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.

Q4 Investor Conferences
Management will also be participating in the following investor healthcare conferences:

• The Guggenheim Inaugural Global Healthcare Conference in a fireside chat featuring Paul J. Diaz, President and CEO, on Wednesday, November 13, 2024 at 3:30 pm ET.
• The 6th Annual Wolfe Research Healthcare Conference in a fireside chat featuring Scott Leffler, Chief Financial Officer, and Sam Raha, Chief Operating Officer, on Wednesday, November 20, 2024 at 3:20 pm ET.

Live and archived webcasts of all presentations can be viewed at investor.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Glenn Farrell 
(385) 318-3718 
PR@myriad.com

FAQ

When will Myriad Genetics (MYGN) release Q3 2024 earnings?

Myriad Genetics will release its Q3 2024 earnings on November 7, 2024, after market close, with a conference call scheduled for 4:30 pm ET.

Which investor conferences will Myriad Genetics (MYGN) attend in November 2024?

Myriad Genetics will participate in the Guggenheim Inaugural Global Healthcare Conference on November 13 and the 6th Annual Wolfe Research Healthcare Conference on November 20, 2024.

How can investors access Myriad Genetics (MYGN) Q3 2024 earnings call?

Investors can access the earnings call through a live webcast on Myriad's Investor Relations website at investor.myriad.com, or via telephone by registering to receive a dial-in number and unique PIN.